Close

JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78

Go back to JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78

Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder

October 20, 2016 4:00 PM EDT

Once-Daily ALKS 5461 Significantly Improved Depression Scores in Patients With Inadequate Response to Standard Antidepressant Therapies

Company to Request Meeting with FDA to Discuss Next Steps for Potential Regulatory Submission

Management to Hold Conference Call Today at 5:00 p.m. EDT

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today announced positive topline... More